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High blood pressure is common during the acute phase of
stroke and is associated with a poor outcome. However, the
management of high blood pressure remains unclear. The ‘Effi-
cacy of Nitric Oxide in Stroke’ trial tested whether transdermal
glyceryl trinitrate, a nitric oxide donor that lowers blood pres-
sure, is safe and effective in improving outcome after acute
stroke. Efficacy of Nitric Oxide in Stroke is an international
multicenter, prospective, randomized, single-blind, blinded
endpoint trial, with funding from the UK Medical Research
Council. Patients with acute ischemic stroke or intracerebral
hemorrhage and systolic blood pressure 140–220 mmHg were
randomized to glyceryl trinitrate or no glyceryl trinitrate and,
where relevant, to continue or stop prestroke antihyperten-
sive therapy. The primary outcome is shift in modified Rankin
Scale at three-months. Patients or relatives gave written
informed (proxy) consent, and all sites had research ethics
approval. Analyses will be done by intention to treat. This
paper and attachment describe the trial’s statistical analysis
plan, developed prior to unblinding of date. The statistical
analysis plan contains design and methods for analyses, and
unpopulated tables and figures for the two primary publica-
tions and some secondary publications. The database will be
locked in late February 2014 in preparation for presentation of
the results in May 2014. The data from the trial will improve
the precision of the estimates of the overall treatment effects
(efficacy and safety) of results from completed trials of blood
pressure management in acute stroke, and provide the first
large-scale randomized evidence on transdermal glyceryl trini-
trate, and of continuing (vs. stopping) prestroke antihyperten-
sive medications, in acute stroke.
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High blood pressure (BP) is present in 70% or more of patients
with acute ischemic stroke and intracerebral hemorrhage (ICH)
(1). Affected patients have a worse outcome, whether judged as
early recurrence, death within a few weeks, or combined death
and dependency after several months (1–4). Lowering BP might
therefore reduce these events and improve functional outcome
providing that cerebral perfusion is not reduced in the presence of
dysfunctional cerebral autoregulation. However, recent large trials
have been inconsistent and inconclusive in their results (5,6).
Nitric oxide (NO) donors are candidate treatments for acute
stroke: NO is a cerebral and systemic vasodilator, modulates vas-
cular and neuronal function, and inhibits apoptosis (7).
Preclinical studies of cerebral ischemia found that NO donors
reduce stroke lesion size and improve regional cerebral blood flow
(CBF) and functional outcome (8). Five small clinical studies of
NO donors have been performed, these involving a total of 208
patients with recent stroke.
Intravenous sodium nitroprusside reduced BP without altering
CBF and exhibited antiplatelet effects (thereby precluding its use
in ICH) (9). Four pilot trials of transdermal glyceryl trinitrate
(GTN) found that it lowered BP by approximately 8%; did not
alter platelet function (and so could be given in ICH); did not
alter middle cerebral artery blood flow velocity or regional CBF;
improved aortic vascular compliance; and could be given to
patients with dysphagia (10–13). No safety concerns were present
in these studies, and in one small trial, ultra-acute treatment with
GTN was associated with an improved functional outcome
(13,14).
On the basis of these preclinical and clinical data showing
feasibility, tolerability and apparent safety of GTN, and the poten-
tial for efficacy, the large ‘Efficacy of Nitric Oxide in Stroke’
(ENOS) trial was started and is ongoing. ENOS is assessing, in a
partial, factorial, prospective, randomized, single-blind, blinded-
outcome design, whether to lower BP with GTN (vs. no GTN)
and whether to continue (vs. stop) prestroke antihypertensive
therapy. The trial commenced in 2001, and protocols for the main
trial and an outline on the management of neuroimaging were
published in 2006 and 2007, respectively (15,16). Several
nontreatment-related and blinded analyses of the ENOS database
have been published since the start of the trial (17–22). The inde-
pendent Data Monitoring Committee have assessed the trial every
six-months and on each occasion recommended that the trial
should continue.
Prior to presentation of the primary analyses in 2014, two
further publications are planned, the statistical analysis plan
(SAP) and a detailed listing of baseline characteristics. The
accompanying Supporting Information Appendix S1 details the
SAP and is presented prior to locking of the trial database
(expected in late February) so that analyses are not data driven or
selectively reported (23). Unusually, this SAP includes not just
information on the two primary publications (GTN vs. no GTN,
and continue vs. stop prestroke antihypertensive medication) but
also provides detailed information on the intended baseline char-
acteristics publication and the first set of secondary publications.
The SAP also informs much of the content of the final trial report
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to be submitted to the Medical Research Council/Efficacy and
Mechanism Evaluation Programme (EME); the final report will
be submitted in the third quarter of 2014 for publication in the
EME Journal, part of the National Institute for Health research
collection of peer-reviewed open access journals.
Importantly, the ENOS Trial Steering Committee have changed
the original plan for the analysis of the primary outcome, as
reported in the protocol (published in IJS) (15), from using an
unadjusted binary ‘cut’ of the modified Rankin Scale (mRS (24),
unadjusted comparison of mRS >2 between the treatment
groups) to an adjusted ordinal analysis utilizing all seven levels of
the mRS with adjustment for minimization variables. The change
meant that the sample size could be reduced from 5000 patients to
a minimum of 3500 patients assuming power of 90% and signifi-
cance of 5%. The decision to change from dichotomous to poly-
tomous analysis was not based on any interim analysis of the
ENOS dataset; rather, it reflects the recognition that ordinal
analyses are more efficient statistically (i.e. they provide improved
statistical power for a given sample size) (25,26) as also shown for
head injury trials (27). (The importance of this change is high-
lighted by recent trials that were technically neutral on their
primary outcome when using a binary analysis but positive when
analyzed secondarily using an ordinal analysis. (6,28)) Similarly,
adjusted analyses provide additional statistical power (29), are
important if minimization is used during the process of random-
ization (30), and help address any minor imbalances present at
baseline because of chance. As a result, these statistical approaches
are likely to be more sensitive to any treatment effect and, as such,
are recommended by the European Stroke Organization (31). The
collection of all baseline data needed for covariate adjustment of
the primary outcome should mean there is no need for imputa-
tion for missing data.
In the future, data from ENOS will be integrated into indi-
vidual patient data meta-analyses of NO donors, and BP lower-
ing, for acute stroke (the latter through the ‘Blood pressure in
Acute Stroke Collaboration’), and made available to participating
countries and the ‘Virtual International Stroke Trials Archive’
(32).
Ultimately, a subset of the data will be made available over the
web, as with the International Stroke Trial (33). Similarly, anony-
mized baseline and on-treatment neuroimaging data will be pub-
lished (16).
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